Tirzepatide (Mounjaro/Zepbound) Price Planning Guide
General price guidance and questions for your provider
Tirzepatide is a dual GIP/GLP-1 receptor agonist that provides significant weight loss by targeting two gut hormones.
These national editorial estimates lack published row-level sources and collection dates. They are not verified market data or local quotes. Read the price-index limitations.
- National editorial estimate: $400–$1,500 per month
- Session length: Weekly injection
- Request itemized local quotes to compare prices
- Red flags to watch for when comparing providers
- Compare price and provider credentials separately
Directory snapshot generated
Get your free report
Enter your email and we'll send the full pricing breakdown.
Tirzepatide (Mounjaro/Zepbound) Pricing FAQ
How is tirzepatide different from semaglutide?+
Tirzepatide targets two receptors (GIP and GLP-1) compared to one for semaglutide, often resulting in greater weight loss.
How much weight can I lose?+
In the FDA label's 72-week Zepbound study of adults without diabetes, mean body-weight change ranged from -15.0% at 5 mg to -20.9% at 15 mg, versus -3.1% with placebo; all groups received diet and activity intervention. Individual outcomes vary.
What are common side effects?+
Similar to semaglutide: nausea, diarrhea, and decreased appetite, typically mild and temporary.